Abbvie Inc. vs Alnylam Pharmaceuticals, Inc.
ABBV vs ALNY — side-by-side comparison from reported financials. ABBV leads 5, ALNY leads 5 of 10 comparable metrics.
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
Alnylam Pharmaceuticals, Inc.
ALNY · Healthcare
$232.60+3.59%Strong
| Metric | ABBV | ALNY |
|---|---|---|
| Price | $276.43 | $232.60 |
| Market cap | $488B | $31.1B |
| Revenue (TTM) | $64.4B | $4.80B |
| Revenue growth | +1.8% | +53.0% |
| Net margin | 9.8% | 16.8% |
| Free cash flow | $18.2B | $794M |
| Net cash (debt) | ($56.2B) | — |
| 1-year price return | +19.8% | -49.1% |
| P/E | 77.4 | 38.5 |
| P/E vs own history (cheap-side %) | 23% | 92% |
| Dividend yield | 2.45% | — |
| Return on equity | 96% | 94% |
| Altman Z-score | 2.33 | 4.40 |
| CV checks passed | 9 of 11 | 8 of 11 |
| Employees | 57,000 | 2,500 |
Full résumé-style profiles: ABBV CV · ALNY CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.